The Division of Gynecologic Oncology has a research program under the direction of
Stephen Cannistra, M.D., head of Gynecologic Medical Oncology at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. The program includes a number of ongoing projects, including investigation into the role of microarrays in predicting response to chemotherapy for patients with ovarian cancer, and a number of clinical trials investigating the role of new therapies for such patients. Perhaps most exciting is the study of new biologic therapies for advanced ovarian cancer, such as angiogenesis inhibitors. Many of the clinical trials are open through the collaborative efforts of the institutions comprising the Dana-Farber/Harvard Cancer Center, of which Beth Israel Deaconess is a founding member. The program also maintains a tumor bank for use in basic science investigations in ovarian cancer.